Clinical Trial Update: 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis [Phase 3]

View source ↗

Summary

A 5-year safety study of pimecrolimus cream 1% in infants aged 3-12 months with mild to moderate atopic dermatitis has completed Phase 3 with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Pimecrolimus Cream 1% (pimecrolimus)

Snippet

Sponsor: MEDA Pharma GmbH & Co. KG | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2013-01-16